Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients.
Approximately half of breast cancer patients with stage I-III disease will suffer metastatic disease despite resection with tumour-free margins. In 30-40% of these patients, individual carcinoma cells can already be detected at the time of primary therapy in cytological bone marrow preparations using immunocytochemistry. Numerous prospective clinical studies have shown that the presence of occult metastatic cells in bone marrow is prognostically relevant to patient survival. Only a few studies failed to do so, thus stimulating a critical discussion on the methodology and clinical value of bone marrow analysis. The potential for obtaining improved prognostic information on patient outcome, for monitoring tumour cell eradication during adjuvant and palliative systemic therapy, and for specifically targeting tumour biological therapies are intriguing clinical opportunities that may be afforded by bone marrow analysis. Standardized and robust methodology is a prerequisite for clinical application of these techniques, however.
Braun
S
S
Department of Obstetrics and Gynecology, Clinical Research Unit, Technical University, Munich, Germany. stephan.braun@lrz.tum.de
Harbeck
N
N
D001854:Bone Marrow Cells / Q000166:cytology*; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009362:Neoplasm Metastasis; D016133:Polymerase Chain Reaction; D011379:Prognosis